Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthtech Industry Analysis

UpdatedApr 05, 2026
DataAggregated Company Financials
Companies67
  • 7D0.06%
  • 3M-26.8%
  • 1Y-30.0%
  • YTD-25.4%

The Healthtech industry has been flat over the last week, but Doximity has lost 3.9%. Unfortunately though, the industry is down 30% over the past 12 months. Looking forward, earnings are forecast to grow by 21% annually.

Industry Valuation and Performance

Has the U.S. Healthtech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 05 Apr 2026US$46.8bUS$13.6b-US$416,162,415.0032x-112.5x3.4x
Tue, 03 Mar 2026US$49.5bUS$13.5b-US$343,986,340.0039.2x-144x3.7x
Thu, 29 Jan 2026US$61.0bUS$13.6b-US$102,102,340.0047.5x-597.7x4.5x
Sat, 27 Dec 2025US$64.4bUS$13.6b-US$102,572,340.0054.2x-627.9x4.7x
Mon, 24 Nov 2025US$69.7bUS$13.6b-US$117,958,271.0052.4x-591.1x5.1x
Wed, 22 Oct 2025US$79.7bUS$13.1b-US$211,110,296.0058.7x-377.7x6.1x
Fri, 19 Sep 2025US$78.1bUS$13.2b-US$266,647,296.0058.6x-292.9x5.9x
Sun, 17 Aug 2025US$77.2bUS$13.1b-US$364,716,795.0058.7x-211.7x5.9x
Tue, 15 Jul 2025US$77.1bUS$13.2b-US$1,382,394,447.0055.4x-55.8x5.8x
Thu, 12 Jun 2025US$78.9bUS$13.2b-US$1,382,393,022.0060.7x-57.1x6x
Sat, 10 May 2025US$70.9bUS$13.1b-US$1,463,322,959.0056.7x-48.4x5.4x
Mon, 07 Apr 2025US$62.9bUS$13.2b-US$1,414,656,089.0048.7x-44.4x4.8x
Wed, 05 Mar 2025US$69.9bUS$13.1b-US$1,568,031,514.0063.2x-44.6x5.4x
Fri, 31 Jan 2025US$71.5bUS$12.9b-US$1,638,054,514.0060.5x-43.7x5.6x
Sun, 29 Dec 2024US$66.8bUS$12.9b-US$1,636,315,514.0055x-40.8x5.2x
Tue, 26 Nov 2024US$64.3bUS$12.8b-US$1,712,780,390.0056x-37.6x5x
Thu, 24 Oct 2024US$64.8bUS$13.5b-US$3,126,871,151.0053x-20.7x4.8x
Sat, 21 Sep 2024US$66.1bUS$14.0b-US$3,302,096,821.0055.8x-20x4.7x
Mon, 19 Aug 2024US$60.2bUS$13.9b-US$3,360,989,829.0056.7x-17.9x4.3x
Wed, 17 Jul 2024US$58.1bUS$13.7b-US$1,860,692,542.0053x-31.2x4.2x
Fri, 14 Jun 2024US$58.5bUS$13.7b-US$1,889,788,216.0047.3x-31x4.3x
Sun, 12 May 2024US$56.3bUS$12.8b-US$1,992,747,742.0047x-28.3x4.4x
Tue, 09 Apr 2024US$61.3bUS$12.7b-US$1,619,729,105.0051.6x-37.8x4.8x
Thu, 07 Mar 2024US$63.3bUS$14.1b-US$1,445,414,794.0048.3x-43.8x4.5x
Sat, 03 Feb 2024US$72.4bUS$18.3b-US$5,780,316,752.0058.7x-12.5x3.9x
Mon, 01 Jan 2024US$72.5bUS$18.3b-US$5,781,192,665.0058.4x-12.5x4x
Wed, 29 Nov 2023US$65.0bUS$18.2b-US$5,807,346,665.0052x-11.2x3.6x
Fri, 27 Oct 2023US$65.4bUS$18.1b-US$5,551,631,965.0048.9x-11.8x3.6x
Sun, 24 Sep 2023US$69.2bUS$18.0b-US$5,514,972,389.0050.4x-12.6x3.8x
Tue, 22 Aug 2023US$69.7bUS$17.9b-US$5,554,149,562.0050.9x-12.5x3.9x
Thu, 20 Jul 2023US$80.1bUS$17.7b-US$8,580,548,318.0061.8x-9.3x4.5x
Sat, 17 Jun 2023US$76.1bUS$17.7b-US$8,581,046,209.0062.9x-8.9x4.3x
Mon, 15 May 2023US$70.2bUS$17.6b-US$8,595,476,164.0057.2x-8.2x4x
Wed, 12 Apr 2023US$72.7bUS$17.4b-US$14,978,932,055.0057.6x-4.9x4.2x
Price to Earnings Ratio

-4.9x


Total Market Cap: US$72.7bTotal Earnings: -US$14,978,932,055.00Total Revenue: US$17.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthtech Industry Price to Earnings3Y Average -125.2x202420252026
Current Industry PE
  • Investors are pessimistic on the American Healthcare Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 4.7x is higher than the industry's current PS ratio of 3.4x.
Past Earnings Growth
  • The earnings for companies in the Healthcare Services industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 8.0% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market3.46%
Healthcare3.50%
Healthtech0.06%
Healthtech0.06%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
VEEV Veeva SystemsUS$173.980.8%
+US$227.0m		-18.6%PE31.3x
WAY Waystar HoldingUS$23.740.8%
+US$38.3m		-32.0%PE40.6x
GDRX GoodRx HoldingsUS$2.055.7%
+US$37.7m		-50.2%PE23.1x
SDGR SchrödingerUS$11.584.5%
+US$36.9m		-35.8%PS3.3x
CTEV ClaritevUS$17.4612.4%
+US$31.8m		-12.7%PS0.3x

Latest News

LFMD
US$3.51
LifeMD
7D
-5.6%
1Y
-32.0%

LFMD: GLP 1 Virtual Care Expansion Will Drive Telehealth Reacceleration

Analysts have trimmed the fair value estimate for LifeMD slightly to $14.17 from $14.22, as updated assumptions around higher expected revenue growth, improved profit margins, and a lower future P/E multiple are weighed against recent price target increases tied to stronger 2026 outlooks and GLP-1 driven virtual care expansion. Analyst Commentary Recent Street research has turned more constructive on LifeMD, with several bullish analysts revisiting their models and price targets following the latest quarterly update and 2026 outlook.
SDGR
US$11.58
Schrödinger
7D
4.5%
1Y
-35.8%

SDGR: Hosted Software Transition Will Set Up 2026 Demand Reappraisal

Narrative Update on Schrödinger The average analyst price target for Schrödinger has reset toward $13, with recent cuts from $33 to $24, $28 to $25, $24 to $20, and $18 to $13 reflecting concerns about near term revenue pressure from the shift toward hosted software and ongoing debate about appropriate valuation multiples, even as analysts highlight stable demand indicators and maintain a mix of Buy, Overweight, Equal Weight, and Neutral views. Analyst Commentary Recent research on Schrödinger shows a cluster of price target resets and overall cautious positioning, even where ratings remain constructive.
CERT
US$5.41
Certara
7D
-5.9%
1Y
-43.4%
TBRG
US$16.24
TruBridge
7D
15.4%
1Y
-36.3%

TBRG: Revenue Cycle Momentum And EHR Stability Will Support Future Re Rating

Analysts have trimmed their price targets on TruBridge, with the average moving from about $22.67 to $21.00 as they weigh a slightly higher discount rate, modestly different revenue growth and margin assumptions, and a lower future P/E multiple against the company's mix of Revenue Cycle Management growth potential and stable Electronic Health Records operations. Analyst Commentary Recent research updates on TruBridge reflect a mix of optimism around the business model and caution around execution and valuation.
PHR
US$8.37
Phreesia
7D
-23.8%
1Y
-65.6%
ITOC
US$0.31
iTonic Holdings
7D
-22.5%
1Y
-90.9%
SCNX
US$0.30
Scienture Holdings
7D
-28.9%
1Y
-69.2%
TDOC
US$5.27
Teladoc Health
7D
2.5%
1Y
-27.7%
CCLD
US$3.35
CareCloud
7D
-4.0%
1Y
165.9%

CCLD: Clearer Organic Revenue Disclosure Will Support Future Upside Potential

Narrative Update on CareCloud Analysts have reduced their CareCloud price target to $3.25, reflecting concerns that recent acquisitions and the planned aircraft purchase may be masking underlying revenue declines rather than supporting a stronger long term outlook. Analyst Commentary Recent commentary points to a cautious stance on CareCloud, with the current US$3.25 price target described as reflecting concern that acquisitions and the planned aircraft purchase may be masking underlying revenue pressure rather than supporting a clearer long term growth story.
GDRX
US$2.05
GoodRx Holdings
7D
5.7%
1Y
-50.2%
WAY
US$23.74
Waystar Holding
7D
0.8%
1Y
-32.0%

WAY: Expanded Google Cloud AI Partnership Will Support Future Earnings Power

Analysts have slightly adjusted their price target for Waystar Holding to about $36.77 from $37.00. This change reflects updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E that remain broadly consistent with prior views.
SOPH
US$5.04
SOPHiA GENETICS
7D
7.2%
1Y
82.6%

SOPH: Higher Future P/E And New U.S. Partnerships Will Support Upside

Analysts raised their price target on SOPHiA GENETICS by $1, reflecting updated views on factors such as revenue growth expectations, discount rate assumptions, profit margin outlook, and a recalibrated future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as better aligning the stock with updated expectations for revenue growth, which they view as supportive of a richer valuation multiple.
VEEV
US$173.98
Veeva Systems
7D
0.8%
1Y
-18.6%

VEEV: AI Adoption In R&D Workflows Will Support Durable Premium Outlook

Analysts have adjusted their price targets on Veeva Systems into a roughly $190 to $317 range, generally trimming prior targets by tens of dollars as software valuation multiples compress, even after what they describe as solid Q4 results and broadly constructive longer term fundamentals. Analyst Commentary Recent research paints a mixed but generally constructive picture for Veeva Systems, with most firms trimming price targets while still pointing to solid execution and durable fundamentals.
HSTM
US$20.45
HealthStream
7D
-3.1%
1Y
-34.6%

HSTM: AI Disruption Risks And Capital Returns Will Shape Future Outlook

Analysts have reset their price target on HealthStream to $21, down from $25, after incorporating fresh views on AI-related risks and management's argument that the company is relatively well positioned compared with other SaaS names. Analyst Commentary Bearish analysts have trimmed expectations on HealthStream by cutting the price target to $21 from $25, while maintaining a neutral stance on the shares.
DOCS
US$22.77
Doximity
7D
-3.9%
1Y
-55.6%

DOCS: AI Tools And Buybacks Will Shape A Cautious Balanced Outlook

Analysts held the Doximity fair value estimate steady at $25.00, while modestly adjusting assumptions after mixed but generally constructive price target moves that highlight interest in the platform's AI tools, network effects, and healthcare marketing exposure. Analyst Commentary Recent Street research on Doximity reflects a split view, with some firms highlighting the medical AI tool suite, network effects and healthcare marketing exposure, while others reset expectations through lower price targets and more neutral ratings.
CTEV
US$17.46
Claritev
7D
12.4%
1Y
-12.7%